There are, at present, several once weekly GLP-1 receptor agonists available in the market: exenatide long-acting release (LAR), albiglutide, dulaglutide and semaglutide.74,75 Head-to-head clinical trials data suggest that long-acting GLP-1 receptor agonists produce superior glycemic control when compared with their shortacting counterparts (exenatide and liraglutide)
The Bridge program is directly administered by CMS at a net price CMS has negotiated of $249 (with a $50 copay for Medicare patients) and completely bypasses the Part D PBM ecosystem
Complementary pituitary pathways studied for enhanced downstream IGF-1 output versus monotherapy
The peptide also inhibited appetite and food intake
has served as a paid consultant for Novo Nordisk, Eli Lilly, CinRx, Fractyl, Structure Therapeutics, Crinetics, Amgen, Congruence Therapeutics and Nuanced Health